Forward looking statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company.

These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP to non-GAAP financial results is provided under the investor section of Myriad’s corporate website at www.myriad.com.
Who we are, what we do, and why it matters

Illuminating the path to better health through genetic insights.

Our purpose-led Mission

We advance health and wellbeing for all, empowering every individual by revealing the answers inside each of us.

Our Vision

As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health, and enable healthcare providers to better detect, treat and prevent disease.

Health. Illuminated.
# Third quarter operating and financial highlights

<table>
<thead>
<tr>
<th>Core Volume Growth Continues</th>
<th>HCT &amp; GeneSight Volume Growth Ramping</th>
<th>Pricing Stable with Visibility into Medicare Rate</th>
<th>Gross Margin Stable YTD</th>
<th>Tuck In Acquisition Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>+12%</strong> YOY 3Q test volume growth, excluding divested businesses</td>
<td><strong>+4%</strong> YOY 3Q Hereditary Cancer Testing (HCT) volumes returns to growth GeneSight quarterly volumes grew 34% YOY in 3Q</td>
<td>MolDx program assigned the MyRisk hereditary cancer test CPT code 81479 and assigned test specific pricing at $1,743.95 per test</td>
<td><strong>+70%</strong> YTD Gross Margin and disciplined cost management leading to 5% YOY increase in adjusted operating expense for the third quarter of 2022</td>
<td>Acquired Gateway Genomics, a personal genomics company and developer of consumer genetic tests serving the women’s health market</td>
</tr>
</tbody>
</table>
Building on strong Women’s Health franchise

Personal genomics company with the mission to develop leading-edge genetic tests that give families a new level of understanding about their future children

**Transaction rationale**

- Alignment with core Women’s Health; Moving closer to the customer
- Strong brand reputation; 76-point Net Promoter Score (NPS)
- Expands brand awareness through consumer influence
- Synergy opportunities with Myriad Genetics customer base
- High revenue growth (forecast 20%+ CAGR over next 3-5 years)

**Transaction price**

- Cash purchase price of $67.5 million; Earn-out of up to $32.5 million upon the achievement of certain revenue, volume synergy and earnings-based targets
Active pipeline to drive long-term accelerating growth

FirstGene
Women's Health
4-in-1 prenatal screening

**What is It?** Single integrated assay for NIPS, carrier screen, fetal recessive status and feto-maternal blood compatibility on a single blood draw on one person

- **Market opportunity (SAM):** >1M patients
- **Key advantages vs. competitors:** Fewer inconclusive fetal recessive results, faster turnaround time; 3x lower cost of goods
- **Established reimbursement**

**Target launch:** 2H23

Precise Liquid
Oncology
Robust tumor profiling & therapy selection

**What is It?** Comprehensive genomic profiling test; may serve as first-line offering or as reflex if solid tumor is insufficient

- **Market opportunity (SAM):** <300k patients
- **Key Advantages:** Panel size ~2x size (500 genes) of lead competitor; Precise uses both DNA/RNA; ease of use as part of Precise Oncology Solutions suite
- **Established reimbursement path**

**Target launch:** 2H23

Precise MRD
Oncology
Minimal residual disease monitoring

**What is It?** Monitoring test based on whole genome sequencing to deeply interrogate tumor and detect recurrence earlier and help guide treatment decisions

- **Market opportunity (SAM):** ~1M patients
- **Key Advantages vs competitors:** targets 10x variants
- **Known path to reimbursement**

**Target launch:** RUO mid-23
Nicole Lambert, Chief Operating Officer
Mental Health: Setting another record

Using genetic insights to help physicians understand how genetic alterations impact patient response to antidepressants and other drugs.

Quarterly highlights

- Surpassed 2 million patients worldwide with GeneSight to date
  - Over two years of sequential quarterly volume growth
- Achieved highest ever quarterly volume level in the third quarter
- In September, reached an all-time high of monthly sales leads
  - Increasing awareness driven by digital search, SEO and lead form optimization

Operating Results

- Q3 ’22 volume: ~97k
- Q3 ’22 revenue: $33.0M
Leading health and wellness with best-in-class genetic insights for women of all ancestries, assessing cancer risk and offering prenatal solutions.

**Operating Results**
- Q3 '22 volume: ~112k
- Q3 '22 revenue: $54.3M

**Quarterly highlights**
- Women’s Health hereditary cancer testing volumes returned to growth in the third quarter
  - Momentum going into the fourth quarter of 2022
- Myriad Complete suite of services increasing utilization in current provider base
- Tech-enabled tools continue to improve provider & patient ease of use
- Rollout of Women’s Health portal shifts to the fourth quarter of 2022
Oncology: Build on strong Hereditary Cancer Position & FDA approved companion diagnostic tests

Clarifying cancer treatment with genetic insights and companion diagnostic tests that are designed to work with corresponding drugs and treatments.

**Operating Results**
- Q3 ‘22 volume: ~47k
- Q3 ‘22 revenue: $69.2M

**Quarterly highlights**
- Precise Tumor volume levels and adoption rate continue to grow
  - Strong attachment rate to other Myriad Oncology products
- Positive feedback from oncologists regarding the Precise integrated results summary with new iterations to come
  - Precise integrated results summary provides quick results and key insights allowing oncologists to streamline their decision making process

---

**MyRisk™**
Hereditary Cancer Test

**MyChoice™ CDx**
Myriad HRD Companion Diagnostic Test

**EndoPredict™**
Breast Cancer Prognostic Test

**Prolaris™**
Prostate Cancer Prognostic Test

**BRACAnalysis CDx™**
Germline Companion Diagnostic Test

**Precise™ Tumor**
Molecular Profile Test

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com

1 November 2022
Bryan Riggsbee, Chief Financial Officer
Organic revenue growth driven by GeneSight

Revenue Notes:

- **2% headwind to growth YTD** from $7.1 million impact of currency translation (YTD22) and a $4 million non-recurring milestone payment in third quarter 2021

- **Revenue growth** driven by:
  - HCT volumes **+4% year-over-year** in the third quarter
  - GeneSight: **+40% vol growth YTD**
  - myChoice CDx: **+47% vol growth YTD**
  - Prolaris: double digit vol growth YTD

*Excludes revenue from divested businesses*
Revenue progression reflects normal seasonal trends; 2Q22 - 4Q22E

Takeaways:
- Third quarter reflects normal seasonality offset by growth
- Headwind to third quarter revenue compared to previous quarter includes:
  - ~$17.0 million change of estimates (2Q: +$11.7 million, 3Q: -$5.3 million)
  - ~$3.3 million from the impact of currency translation
  - Normal seasonal trend
- Fourth quarter guidance reflects normal seasonal growth
Adjusted operating expense trends stable in difficult inflationary environment and reflect growth initiatives

- Company continues to manage Adjusted OpEx prudently. Increase driven by:
  - **Strategic investments** in technology and tech-enabled commercial tools
  - **Prioritized spend** in R&D pipeline development
  - **Inflationary pressures** in wages, supply chain, freight, etc.

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Adj OpEx in $ millions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1Q22</td>
<td>$120.0</td>
</tr>
<tr>
<td>2Q22</td>
<td>$125.3</td>
</tr>
<tr>
<td>3Q22</td>
<td>$127.0</td>
</tr>
<tr>
<td>4Q22E</td>
<td>$130.0</td>
</tr>
<tr>
<td>1H22A</td>
<td>$245.3</td>
</tr>
<tr>
<td>2H22E</td>
<td>~$260.0</td>
</tr>
</tbody>
</table>

6% growth in Adj OpEx 1H22A vs 2H22E
## Updated fiscal year 2022 financial guidance

<table>
<thead>
<tr>
<th>($ in millions, except per share amounts)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
</tr>
<tr>
<td>Updated</td>
</tr>
<tr>
<td>Previous</td>
</tr>
<tr>
<td><strong>Change</strong></td>
</tr>
<tr>
<td><strong>Gross Margin %</strong></td>
</tr>
<tr>
<td>Updated</td>
</tr>
<tr>
<td>Previous</td>
</tr>
<tr>
<td><strong>Change</strong></td>
</tr>
<tr>
<td><strong>Operating Expenses</strong></td>
</tr>
<tr>
<td>GAAP</td>
</tr>
<tr>
<td>Updated</td>
</tr>
<tr>
<td>Previous</td>
</tr>
<tr>
<td><strong>Change</strong></td>
</tr>
<tr>
<td><strong>Earnings (Loss) Per Share</strong></td>
</tr>
<tr>
<td>Updated</td>
</tr>
<tr>
<td>Previous</td>
</tr>
<tr>
<td><strong>Change</strong></td>
</tr>
</tbody>
</table>

*Excludes the estimated impact of stock-based compensation of approximately $40.0 million, non-cash amortization associated with acquisitions of approximately $40.0 million and special items such as costs related to transformation initiatives of approximately $15.0 million

### Takeaways:

- **$15 million reduction in full year revenue guidance** driven primarily by **headwinds from change of estimates** (~$5 million) and the estimated impact of currency translation (~$7 million)

- **Gross margins** shift to lower end of previous guidance range due to impact of change of estimates and currency translation

- Operating expense guidance increased modestly to reflect the **impact of inflation** as well as investments made in technology, research & development, and commercial tools
Investment case: strengths and strategic advantages

Leader in genetic testing and precision medicine

- Growing test volumes
- Price stability & visibility
- Disciplined investment & cost management
- Effective capital deployment
- Future catalysts: robust pipeline supported by emerging enterprise, tech, and commercial capabilities
Q&A
Thank you